Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Weiss

Ophthalmology New Hyde Park, NY Medical Doctor

NPI 1114079746 CMS profile 277663

2001 Marcus Ave, Suite W84, New Hyde Park, NY 11042

Open in the dashboard

General payments

$751

15 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Weiss of New Hyde Park, NY is reported in the CMS Open Payments database as having received $751 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 1
2023 General $18 1
2022 General $130 2
2021 General $150 1
2020 General $17 1
2019 General $403 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Weiss
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Mark Weiss were reported at $33. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Mark Weiss Ophthalmology median Middle half National median
2019 $403 $258 $104–$655 $163
2020 $17 $126 $45–$321 $114
2021 $150 $205 $76–$534 $132
2022 $130 $266 $100–$678 $149
2023 $18 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $33 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $257 2 payments
  2. Kala Pharmaceuticals, Inc. $119 1 payment
  3. Johnson & Johnson Surgical Vision, Inc. $103 1 payment
  4. Glaukos Corporation $71 1 payment
  5. Sun Pharmaceutical Industries Inc. $55 3 payments
  6. Novartis Pharmaceuticals Corporation $41 2 payments
  7. Boston Scientific Corporation $33 1 payment
  8. Oyster Point Pharma, Inc. $23 1 payment
  9. UCB, Inc. $18 1 payment
  10. Bausch & Lomb, a division of Bausch Health US, LLC $16 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $751 15 payments
Products named General payments · program years 2019–2025
  1. AcrySof IQ VIVITY IOL $150 1 payment
  2. AcrySof IQ PanOptix $150 1 payment
  3. INVELTYS $119 1 payment
  4. AcrySof IQ PanOptix UV IOL $106 1 payment
  5. AcrySof IQ VIVITY $106 1 payment
  6. Catalys Laser System $103 1 payment
  7. iStent inject Trabecular Micro-Bypass Stent System $71 1 payment
  8. Xelpros $55 3 payments
  9. BromSite $40 2 payments
  10. WATCHMAN FLX $33 1 payment
  11. Other $112 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,425

Median for Ophthalmology: 891

Drug cost

$326,788

Median for Ophthalmology: $68,233

Branded share of claims

48.5%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 64 $87,622
Lumigan Bimatoprost Brand 92 $62,052
Xiidra Lifitegrast Brand 18 $26,119
Vyzulta Latanoprostene Bunod Brand 30 $24,846
Cyclosporine Generic 41 $20,323
Timolol Maleate Generic 96 $12,349
Rocklatan Netarsudil Mesylat/Latanoprost Brand 20 $10,922
Miebo Perfluorohexyloctane/Pf Brand 11 $9,462
Simbrinza Brinzolamide/Brimonidine Tart Brand 22 $9,099
Bromfenac Sodium Generic 57 $8,934

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$210,210

Medicare's payments for the services billed

Medicare patients

1,015

Average age 75

Services billed

2,467

596 women, 419 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Diabetes 36%
Ischemic heart disease 30%
Cancer 21%
Osteoporosis 20%
Chronic kidney disease 14%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record